SIREN : 483910220
PHARMACIE DES MARAICHERS is a French company founded 20 years ago, specialized in the sector Activités des sièges sociaux. Based in COLMAR (68000), this company of category PME shows in 2024 a revenue of 3.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 163 235 € | 2 964 620 € | 2 843 053 € | 2 486 317 € | 2 455 358 € | 2 231 721 € | 1 996 230 € | N/C | 1 990 685 € |
| Net income | 115 136 € | 151 218 € | 133 243 € | 134 325 € | 144 492 € | 129 975 € | 91 418 € | 103 440 € | 75 302 € |
| EBITDA | 210 514 € | 239 447 € | 213 412 € | 208 064 € | 214 672 € | 205 417 € | 133 551 € | N/C | 108 167 € |
| Net margin | 3.6% | 5.1% | 4.7% | 5.4% | 5.9% | 5.8% | 4.6% | N/C | 3.8% |
In 2024, PHARMACIE DES MARAICHERS achieves revenue of 3.2 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +6.0%. Vs 2023: +7%. After deducting consumption (2.3 M€), gross margin stands at 897 k€, i.e. a rate of 28%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 211 k€, representing 6.7% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 115 k€, i.e. 3.6% of revenue. This profit can be retained or distributed to shareholders.
3 163 235 €
897 005 €
210 514 €
193 784 €
115 136 €
6.6%
The debt ratio (= Financial debt / Equity x 100) stands at 151%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 34%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 8.3 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 4.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
150.834%
34.317%
4.395%
8.326
72.5%
In 2024, the debt ratio of PHARMACIE DES MARAICHERS (150.83) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of PHARMACIE DES MARAICHERS (34.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of PHARMACIE DES MARAICHERS (8.33) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 209.32. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 19.5x. Operating income very largely covers interest expenses: high safety margin.
209.32
19.51
In 2024, the liquidity ratio of PHARMACIE DES MARAICHERS (209.32) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of PHARMACIE DES MARAICHERS (19.5x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 6 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 37 days. Excellent situation: suppliers finance 31 days of the operating cycle (retail model). Inventory turnover is 29 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 36 days of revenue, i.e. 317 k€ to permanently finance. Over 2016-2024, WCR increased by +88%, requiring additional financing.
317 178 €
6 j
37 j
29 j
36 j
Based on 103 transactions of similar company sales in 2024, the value of PHARMACIE DES MARAICHERS is estimated at 1 106 870 € (range 337 139€ - 2 189 369€). With an EBITDA of 210 514€, the sector multiple of 5.0x is applied. The price/revenue ratio is 0.38x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 103 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PHARMACIE DES MARAICHERS with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sièges sociaux
The revenue of PHARMACIE DES MARAICHERS in 2024 is 3.2 M€.
Yes, PHARMACIE DES MARAICHERS generated a net profit of 115 k€ in 2024.
The headquarters of PHARMACIE DES MARAICHERS is located in COLMAR (68000), in the department Haut-Rhin.
The tax return of PHARMACIE DES MARAICHERS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARMACIE DES MARAICHERS operates in the sector Activités des sièges sociaux (NAF code 70.10Z). See the 'Sector positioning' section above to compare the company with its competitors.